GoAI
Get started
InterCure Ltd. logo

InterCure Ltd.

INCR

NASDAQHealthcareDrug Manufacturers - Specialty & Generic

Open in GoAI

Previous close

$0.8515

−$0.0175 · -2.01%

Aug 21, 4:00 PM ET

INCR company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Sell

Trim exposure — unfavorable risk-reward

Valuation

47

Fair Value

Momentum

36

Weakening

Sentiment

55

Mixed

Risk resilience

32

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

InterCure Ltd., including its subsidiaries, is actively involved in the entire lifecycle of medical cannabis products. This encompasses everything from initial research and cultivation to manufacturing, marketing, and global distribution, serving both the Israeli market and international territories. The company's offerings feature dried cannabis flower alongside cannabis extracts infused with oil. Beyond its core cannabis operations, InterCure also directs investments towards the biomedical sector. Founded in 1994, the firm's main offices are located in Herzliya, Israel.

Industry
Drug Manufacturers - Specialty & Generic
Sector
Healthcare
Headquarters
IL
CEO
Alexander Rabinovich
Listed since
Jan 28, 2019
Employees
285

Market position

Day range

Current $0.8515

52-week range

Current $0.8515

Open
$0.871
Previous close
$0.869
Volume
8.38K
0.19× average
Average volume
44.35K
Average daily volume
Market cap
50.43M USD
Beta
0.57
Market reference 1
50-day average
$4.847
-82.43% below average
200-day average
$4.8034
-82.27% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
300.46M ILS
P/E (TTM)
-3.69×
P/B (TTM)
0.34×
P/S (TTM)
0.57×
EV / EBITDA
-41.2×
Earnings yield
-21.79%
Free cash flow yield
8.11%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
15.06%
Operating margin
-10.08%
Net margin
-13.22%
Return on equity
-9.01%
Return on assets
-5.17%
Return on invested capital
0.97%

Financial health

Debt / equity
0.46×
Current ratio
1.48×
Altman Z-score
-0.07
Piotroski F-score
4 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends48%21%-7%-35%Gross margin, FY2021: 41.48%Gross margin, FY2022: 39.90%Gross margin, FY2023: 29.56%Gross margin, FY2024: 12.66%Gross margin, FY2025: 12.28%Operating margin, FY2021: 12.83%Operating margin, FY2022: 13.03%Operating margin, FY2023: -11.69%Operating margin, FY2024: -28.14%Operating margin, FY2025: 2.49%Net margin, FY2021: 2.13%Net margin, FY2022: 11.53%Net margin, FY2023: -17.43%Net margin, FY2024: -28.38%Net margin, FY2025: -13.22%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 41.48%. Gross margin FY2022 39.90%. Gross margin FY2023 29.56%. Gross margin FY2024 12.66%. Gross margin FY2025 12.28%. Operating margin FY2021 12.83%. Operating margin FY2022 13.03%. Operating margin FY2023 -11.69%. Operating margin FY2024 -28.14%. Operating margin FY2025 2.49%. Net margin FY2021 2.13%. Net margin FY2022 11.53%. Net margin FY2023 -17.43%. Net margin FY2024 -28.38%. Net margin FY2025 -13.22%.

Income trends

Revenue

270.2M ILS+13.13%

Operating income

6.73M ILS+73.94M ILS

Net income

−35.71M ILS+47.33%
Income trends across reported periods434.33M ILS251.74M ILS69.15M ILS−113.44M ILSRevenue, FY2021: 219.68M ILSRevenue, FY2022: 388.68M ILSRevenue, FY2023: 355.55M ILSRevenue, FY2024: 238.85M ILSRevenue, FY2025: 270.2M ILSOperating income, FY2021: 28.19M ILSOperating income, FY2022: 50.63M ILSOperating income, FY2023: −41.57M ILSOperating income, FY2024: −67.21M ILSOperating income, FY2025: 6.73M ILSNet income, FY2021: 4.69M ILSNet income, FY2022: 44.82M ILSNet income, FY2023: −61.96M ILSNet income, FY2024: −67.8M ILSNet income, FY2025: −35.71M ILSFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 219.68M ILS. Revenue FY2022 388.68M ILS. Revenue FY2023 355.55M ILS. Revenue FY2024 238.85M ILS. Revenue FY2025 270.2M ILS. Operating income FY2021 28.19M ILS. Operating income FY2022 50.63M ILS. Operating income FY2023 −41.57M ILS. Operating income FY2024 −67.21M ILS. Operating income FY2025 6.73M ILS. Net income FY2021 4.69M ILS. Net income FY2022 44.82M ILS. Net income FY2023 −61.96M ILS. Net income FY2024 −67.8M ILS. Net income FY2025 −35.71M ILS.
Metric (ILS)FY2025FY2024FY2023FY2022FY2021
Revenue270.2M ILS238.85M ILS355.55M ILS388.68M ILS219.68M ILS
Cost of goods sold237.02M ILS208.61M ILS250.46M ILS233.6M ILS128.55M ILS
Gross profit33.18M ILS30.23M ILS105.1M ILS155.08M ILS91.13M ILS
Research and development390K ILS414K ILS388K ILS632K ILS1.24M ILS
Selling, general, and administrative80.41M ILS84.63M ILS86.24M ILS97.32M ILS53.46M ILS
Operating expenses26.45M ILS97.44M ILS146.66M ILS104.46M ILS62.95M ILS
Interest income1.56M ILS2.7M ILS4.55M ILS844K ILS130K ILS
Interest expense19.66M ILS20.65M ILS24.22M ILS14.69M ILS5.05M ILS
Depreciation and amortization17.15M ILS15.37M ILS13.17M ILS11.7M ILS7.39M ILS
Operating income6.73M ILS−67.21M ILS−41.57M ILS50.63M ILS28.19M ILS
Net income−35.71M ILS−67.8M ILS−61.96M ILS44.82M ILS4.69M ILS

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
75%
3 beats, 1 miss, 0 met estimates
Average EPS surprise
+1.39%
4 comparable reports
Latest EPS result
-0.02

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates0.18-0.17-0.51-0.86Q2 '23MissQ3 '23BeatQ3 '23BeatQ2 '24No estimateQ3 '24No estimateQ4 '24No estimateQ2 '25No estimateQ3 '25No estimate
Q2 2023, reported May 16, 2023: actual 0.01, estimate 0.04, surprise -75.00%, Miss. Q3 2023, reported Aug 17, 2023: actual 0.11, estimate 0.08, surprise +37.50%, Beat. Q3 2023, reported Aug 31, 2023: actual 0.11, estimate 0.08, surprise +37.50%, Beat. Q2 2024, reported Apr 1, 2024: actual 0.015, estimate —, surprise —, Comparison unavailable. Q3 2024, reported Aug 30, 2024: actual 0.015, estimate —, surprise —, Comparison unavailable. Q4 2024, reported Dec 13, 2024: actual -0.79, estimate —, surprise —, Comparison unavailable. Q2 2025, reported May 1, 2025: actual -0.015, estimate —, surprise —, Comparison unavailable. Q3 2025, reported Aug 28, 2025: actual -0.015, estimate —, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates115.46M94.35M73.23M52.12MQ2 '23MissQ3 '23MissQ3 '23MissQ2 '24MissQ3 '24No estimateQ4 '24No estimateQ2 '25No estimateQ3 '25No estimate
Q2 2023, reported May 16, 2023: actual 106.18M USD, estimate 111.02M USD, surprise -4.36%, Miss. Q3 2023, reported Aug 17, 2023: actual 102.44M USD, estimate 111.02M USD, surprise -7.73%, Miss. Q3 2023, reported Aug 31, 2023: actual 73.47M USD, estimate 101.58M USD, surprise -27.67%, Miss. Q2 2024, reported Apr 1, 2024: actual 62.87M USD, estimate 101.58M USD, surprise -38.11%, Miss. Q3 2024, reported Aug 30, 2024: actual 62.87M USD, estimate —, surprise —, Comparison unavailable. Q4 2024, reported Dec 13, 2024: actual 56.56M USD, estimate —, surprise —, Comparison unavailable. Q2 2025, reported May 1, 2025: actual 65.01M USD, estimate —, surprise —, Comparison unavailable. Q3 2025, reported Aug 28, 2025: actual 65.01M USD, estimate —, surprise —, Comparison unavailable.

INCR news

globenewswire.com

InterCure Finalizes NIS 230 Million (~US$77 Million) Settlement for War-Related Indirect Damages

Company intends to accelerate the rehabilitation of Canndoc's flagship Nir Oz facility, supporting a return to full production and the Company's expansion in the growing German medical cannabis market

Read source
globenewswire.com

InterCure Secures NIS 22 Million in Private Placement Financing Led by Leading Pharma-Focused Hedge Funds

NEW YORK & HERZLIYA, Israel, June 22, 2026 (GLOBE NEWSWIRE) -- InterCure Ltd. (Nasdaq: INCR) (TASE: INCR) (dba Canndoc) (“InterCure” or the “Company”), today announced that, further to the Company's prior reports…

Read source
globenewswire.com

InterCure Initiates Strategic Review of U.S. Medical Cannabis Opportunities Following Historic Federal Rescheduling and Completes the Initial closing of Botanico Acquisition

First Tranche Closing (50%) of Botanico Transaction Expands International Platform with Exclusive Access to U. S. Genetics, Premium Brands and Advanced AI-Driven Technologies; Company Reports Growing Demand in Germany…

Read source
globenewswire.com

InterCure Initiates Strategic Review of U.S. Medical Cannabis Opportunities Following Historic Federal Rescheduling and Completes the Initial closing of Botanico Acquisition

First Tranche Closing (50%) of Botanico Transaction Expands International Platform with Exclusive Access to U.S. Genetics, Premium Brands and Advanced AI-Driven Technologies; Company Reports Growing Demand in Germany and…

Read source

Corporate actions

Corporate action history

Stock splitUpcoming

Effective Aug 24, 2026

1:5

Stock split

Effective Apr 8, 2021

1:4

INCR peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

Continue in GoAI

Research INCR

research.disclaimer